MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 01-08-2026
Neogen Corporation Total Liabilities 2011-2026 | NEOG
Annual Total Liabilities Neogen Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.37 B | 1.4 B | 1.42 B | 106 M | 79.8 M | 72 M | 57.8 M | 57.8 M | 56.7 M | 47.6 M | 41.2 M | 39 M | 32.3 M | 32.5 M | 30.7 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.42 B | 30.7 M | 323 M |
Quarterly Total Liabilities Neogen Corporation
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.26 B | 1.26 B | 1.37 B | 1.38 B | 1.39 B | 1.37 B | 1.4 B | 1.44 B | 1.45 B | 1.41 B | 1.42 B | 1.38 B | 1.46 B | 93.6 M | 106 M | 106 M | 101 M | 76.7 M | 79.8 M | 79.8 M | 68.2 M | 70 M | 72 M | 61.6 M | 59.7 M | 60.8 M | 57.8 M | 57.8 M | 58.4 M | 59.3 M | 57.8 M | 57.8 M | 60.4 M | 60.1 M | 56.7 M | 56.7 M | 52.5 M | 51.4 M | 45.8 M | 47.6 M | 47.9 M | 43.5 M | 41.2 M | 41.2 M | 39.1 M | 38.8 M | 39 M | 39 M | 37.9 M | 37.4 M | 32.3 M | 32.3 M | 32 M | 31.6 M | 32.5 M | 32.5 M | 31.2 M | 31.1 M | 30.7 M | 30.7 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.46 B | 30.7 M | 342 M |
Total Liabilities of other stocks in the Diagnostics research industry
| Issuer | Total Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
58.6 M | - | -6.23 % | $ 30.6 M |  Germany |
|
Akumin
AKU
|
1.62 B | - | -17.87 % | $ 25.9 M |  Canada |
 |
Bioventus
BVS
|
455 M | $ 8.99 | 1.35 % | $ 599 M |  USA |
 |
Brainsway Ltd.
BWAY
|
14.4 M | $ 13.73 | 0.59 % | $ 99.4 M |  Israel |
 |
Castle Biosciences
CSTL
|
75.4 M | $ 25.9 | 0.27 % | $ 719 M | USA |
 |
Aspira Women's Health
AWH
|
10.6 M | - | -6.19 % | $ 10.5 M | USA |
 |
DexCom
DXCM
|
3.59 B | $ 67.32 | 1.48 % | $ 26.3 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
21.6 M | - | - | $ 562 M |  Britain |
 |
Guardant Health
GH
|
2.11 B | $ 88.75 | 1.8 % | $ 11.1 B | USA |
 |
Charles River Laboratories International
CRL
|
3.92 B | $ 153.71 | 1.14 % | $ 7.62 B | USA |
 |
CareDx, Inc
CDNA
|
110 M | $ 17.6 | 1.62 % | $ 938 M | USA |
 |
Accelerate Diagnostics
AXDX
|
87.3 M | - | -61.36 % | $ 2.46 M | USA |
 |
Exact Sciences Corporation
EXAS
|
3.46 B | $ 103.94 | 0.09 % | $ 19.6 B | USA |
 |
Global Cord Blood Corporation
CO
|
3.65 B | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
186 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
4.37 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
427 M | - | 0.12 % | $ 80.1 M | China |
 |
Fulgent Genetics
FLGT
|
90.8 M | $ 15.43 | 3.21 % | $ 467 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
2.7 B | - | - | $ 10.7 B | USA |
|
Biodesix
BDSX
|
76.4 M | $ 16.59 | -4.05 % | $ 2.15 B | USA |
 |
ICON Public Limited Company
ICLR
|
7.35 B | $ 100.49 | 2.95 % | $ 8.29 B |  Irlanda |
 |
Anixa Biosciences
ANIX
|
2.13 M | $ 2.89 | 1.76 % | $ 93.8 K | USA |
 |
IQVIA Holdings
IQV
|
23.3 B | $ 168.43 | 2.15 % | $ 29 B | USA |
 |
Danaher Corporation
DHR
|
31.8 B | $ 195.21 | 2.0 % | $ 139 B | USA |
 |
Biocept
BIOC
|
22 M | - | -13.05 % | $ 7.29 M | USA |
 |
Heska Corporation
HSKA
|
164 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
12.4 M | - | -20.0 % | $ 1.06 M | USA |
 |
Pacific Biosciences of California
PACB
|
779 M | $ 1.38 | 1.47 % | $ 414 M | USA |
 |
Illumina
ILMN
|
2.7 B | $ 120.84 | 1.31 % | $ 19.2 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
7.16 B | $ 198.61 | -0.17 % | $ 22 B | USA |
 |
QIAGEN N.V.
QGEN
|
3.11 B | - | - | $ 10.6 B |  Niderland |
 |
Agilent Technologies
A
|
5.32 B | $ 112.75 | 0.82 % | $ 34.3 B | USA |
 |
BioNano Genomics
BNGO
|
41.3 M | $ 1.13 | 1.8 % | $ 1.44 M | USA |
 |
DarioHealth Corp.
DRIO
|
7.26 M | $ 8.75 | 3.92 % | $ 248 M | Israel |
 |
NeoGenomics
NEO
|
523 M | $ 8.27 | 0.36 % | $ 1.06 B | USA |
 |
Lantheus Holdings
LNTH
|
1.14 B | $ 80.45 | 2.48 % | $ 5.43 B | USA |
 |
Chembio Diagnostics
CEMI
|
44.8 M | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
1.83 M | - | - | $ 9.42 M | Israel |
 |
Co-Diagnostics
CODX
|
9.31 M | $ 4.4 | 101.83 % | $ 129 M | USA |
 |
Medpace Holdings
MEDP
|
1.52 B | $ 455.15 | 0.33 % | $ 13.1 B | USA |
 |
Motus GI Holdings
MOTS
|
4.54 M | - | -34.28 % | $ 263 K | Israel |
 |
Mettler-Toledo International
MTD
|
3.74 B | $ 1 206.72 | 0.63 % | $ 24.9 B |  Schweiz |
 |
Celcuity
CELC
|
130 M | $ 114.11 | -0.69 % | $ 4.5 B | USA |
 |
DermTech
DMTK
|
64.8 M | - | -11.32 % | $ 2.94 M | USA |
 |
National Research Corporation
NRC
|
121 M | $ 17.73 | 1.9 % | $ 397 M | USA |
 |
Twist Bioscience Corporation
TWST
|
169 M | $ 47.28 | 5.04 % | $ 2.83 B | USA |
 |
Invitae Corporation
NVTA
|
1.85 B | - | - | $ 21.2 M | USA |
 |
Enzo Biochem
ENZ
|
29.7 M | - | -8.98 % | $ 14.8 K | USA |
 |
Natera
NTRA
|
689 M | $ 198.38 | 0.35 % | $ 19.5 B | USA |